ArticleTranslational vision science & technology2025
Machine Learning Applied to Visual Fields of Dominant Optic Atrophy Patients.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Archetypal Visual Field Analysis of Patients With Chronic Leber Hereditary Optic Neuropathy in Relation to Visual Recovery.Investigative ophthalmology & visual science · 2026Article
- Impact of Inner Retinal Layer Thinning on Visual Function in OPA1 Autosomal Dominant Optic Atrophy and Associations With Age and Genetic Variant Class.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Identification and quantification of characteristic visual field (VF) patterns in patients with dominant optic atrophy (DOA) using the archetypal analysis (AA) machine learning algorithm. Methods: In this retrospective study, we collected 30-2 or 24-2 VFs performed with Humphrey Visual Field analyzer from 144 patients (280 eyes) affected by molecularly confirmed DOA carrying OPA1 heterozygous mutation. The VFs were randomly separated into a training set (224 VFs, 80%) and test set (56 VFs, 20%). An AA model was developed by decomposing the VFs of the training set into archetypes (ATs). Spearman correlations were calculated between ATs' weights and mean deviation (MD) and visual acuity (VA). Statistical comparison was performed between ATs weights according to mutation subtype groups. Results: The DOA-AA model was composed of eight ATs with a high performance in the test set (R2 = 0.88). According to the Ocular Hypertension Treatment Study (OHTS) classification, the central/ceco-central scotoma resembling ATs presented the highest weights (24%) followed by superior defects (13%). ATs with more abnormal VF resembling defects correlated most with MD (AT5-8), whereas only the total loss AT7 with VA (P value < 0.01). Subtype mutations linked with worse clinical features had statistically significantly higher weights for worse ATs (AT7, P < 0.001). Conclusions: The developed AA model allowed the identification and quantification of VF patterns in DOA. Furthermore, a clinical genotype-phenotype association was supported by the comparison of severity at VF AA decomposition. Translational Relevance: AA enables an objective identification of quantifiable visual field defects intrinsic to DOA providing functional details based on genotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.